Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531

PURPOSE: The primary objective of the Children’s Oncology Group study ANBL0531 (ClinicalTrials.gov identifier: NCT00499616) was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology- and response-based algorithm to assign treatment duration while maintaining...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Twist, Clare J., Schmidt, Mary Lou, Naranjo, Arlene, London, Wendy B., Tenney, Sheena C., Marachelian, Araz, Shimada, Hiroyuki, Collins, Margaret H., Esiashvili, Natia, Adkins, E. Stanton, Mattei, Peter, Handler, Michael, Katzenstein, Howard, Attiyeh, Edward, Hogarty, Michael D., Gastier-Foster, Julie, Wagner, Elizabeth, Matthay, Katherine K., Park, Julie R., Maris, John M., Cohn, Susan L.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2019
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6881103/
https://ncbi.nlm.nih.gov/pubmed/31386611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00919
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky